Wednesday 03 July 2024
Internal Reference Number: FOI_7126
Date Request Received: 14/04/2023 00:00:00
Date Request Replied To: 05/05/2023 00:00:00
This response was sent via: By Email
Request Summary: Dermatological conditions
Request Category: Companies
| Question Number 1: How many patients were treated in the last 4 months by the dermatology department with each of the following products: • Abrocitinib • Acitretin • Alitretinoin • Azathioprine • Baricitinib • Ciclosporin • Dupilumab • Methotrexate • Mycophenolate mofetil • Pimecrolimus • Phototherapy (UVB or PUVA) • Tacrolimus ointment • Tralokinumab • Upadacitinib | |
| Answer To Question 1: Abrocitinib 0 Acitretin 15 Alitretinoin <5 Azathioprine <5 Baricitinib 0 Ciclosporin 9 Dupilumab 18 Methotrexate 19 Mycophenolate 0 Pimecrolimus 13 Phototherapy 74 Tacrolimus 25 Tralokinumab <5 Upadacitinib 0 | |
| Question Number 2: Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: • Age 6-11 • Age 12-17 • Age 18 and above | |
| Answer To Question 2: Age 6-11 = <5 Age 12-17 = <5 Age 18+ = 71 | |
| Question Number 3: If possible, could you please provide the number of patients treated in the last 4 months for Atopic Dermatitis ONLY with: • Azathioprine • Ciclosporin • Methotrexate • Mycophenolate mofetil • Phototherapy (UVB or PUVA) | |
| Answer To Question 3: Azathioprine <5 Ciclosporin <5 Methotrexate 5 Mycophenolate mofetil 0 UVB <5 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
